← All Avalo Therapeutics, INC filings

Avalo Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
AVTX
Avalo Therapeutics, INC
10-K: Avalo Therapeutics Reports Increased Losses, Eyes Key Trial Data
Avalo Therapeutics reported a significant increase in net loss for 2025, driven by higher R&D and administrative expenses, as it progresses its lead drug candidate, abdakibart, towards a critical Phase 2 data readout in Q2 2026.
NASDAQ
AVTX
Avalo Therapeutics, INC
10-K: Avalo Therapeutics Focuses on AVTX-009 Development, Reports Year-End Financials
Avalo Therapeutics advances AVTX-009, an anti-IL-1 monoclonal antibody, through Phase 2 trials while reporting a net loss of $35.1 million for 2024.
NASDAQ
AVTX
Avalo Therapeutics, INC
10-K: Avalo Therapeutics Focuses on New Lead Asset AVTX-009 After $185 Million Capital Raise
Avalo Therapeutics shifts its primary focus to AVTX-009, an anti-IL-1 monoclonal antibody, following a significant capital raise and the acquisition of AlmataBio.